PLC Systems out of Franklin, MA has received EU’s CE Mark of approval for its RenalGuard System, a device designed to create and maintain a high urine output. The company believes that its system helps the body to rapidly eliminate contrast agent during radiologic procedures, reducing its toxic renal side effect, namely the contrast-induced nephropathy:
Approximately seven million patients worldwide undergo interventional cardiovascular therapeutic and diagnostic imaging procedures each year. Contrast-induced nephropathy, or CIN, is a major and growing problem due to the increasing number of older patients, diabetics and patients with pre-existing renal failure – all of whose conditions make them at risk for CIN when they require interventional procedures that use radiographic contrast media. CIN is the third most common cause of in-hospital acute renal failure…
RenalGuard is based on existing pre-clinical study data that suggests that initiating and maintaining high urine output during imaging procedures allows the body to rapidly eliminate toxins in contrast media, reducing their harmful effects. RenalGuard is a fully-automated, real-time matched fluid replacement device intended for interventional cardiology and radiology patients undergoing imaging procedures using contrast media.
Press release: PLC Systems Receives CE Mark Approval for RenalGuard™…
Product page: RenalGuard …